Madrigal Pharmaceuticals (MDGL) Long-Term Deferred Tax (2016 - 2023)

Madrigal Pharmaceuticals (MDGL) has 8 years of Long-Term Deferred Tax data on file, last reported at $383.2 million in Q4 2023.

• On a quarterly basis, Long-Term Deferred Tax rose 41.36% year-over-year to $383.2 million in Q4 2023; TTM through Dec 2023 was $383.2 million, a 41.36% increase from a year earlier, with the FY2023 full-year figure at $383.2 million, up 41.36% from the prior year.
• Long-Term Deferred Tax for Q4 2023 stood at $383.2 million, up from $271.1 million in the prior quarter.
• Over the last five years, Long-Term Deferred Tax for MDGL reached as high as $383.2 million in Q4 2023 and fell as low as $47.9 million in Q4 2021.
• Historically, Long-Term Deferred Tax has averaged $180.1 million across 5 years, with a median of $132.4 million in 2020.
• Across the five-year window, Long-Term Deferred Tax slumped 63.85% in 2021 and soared 466.41% in 2022, its largest moves.
• Year by year, Long-Term Deferred Tax stood at $65.9 million in 2019, then surged by 101.05% to $132.4 million in 2020, then slumped by 63.85% to $47.9 million in 2021, then surged by 466.41% to $271.1 million in 2022, then soared by 41.36% to $383.2 million in 2023.
• Per Business Quant data, the three most recent Long-Term Deferred Tax figures were $383.2 million in Q4 2023, $271.1 million in Q4 2022, and $47.9 million in Q4 2021.